 |
|
Protein controls blood vessel formation, offers new drug target
December 05, 2007CHAPEL HILL - After an injury, the body grows new blood vessels to repair damaged tissue. But sometimes too much growth causes problems, as when new blood vessels in the eyes leak, causing diabetic retinopathy and blindness if not treated.
A protein called CIB1 discovered by researchers at the University of North Carolina at Chapel Hill School of Medicine appears to play a major role in controlling new blood vessel growth, offering a target for drug treatments to help the body repair itself after injury and control unwanted blood vessel growth.
"In the future, this knowledge may help our ability to control blood vessel growth in disease situations such as wound healing, retinal diseases and diabetes," said Leslie Parise, Ph.D., senior study author and professor and chair of biochemistry and biophysics in the UNC School of Medicine.
The results will appear in an upcoming print issue of the journal Circulation Research and were published online Nov. 1, 2007. The research was funded by the National Institutes of Health.
Parise's lab first discovered the protein, called CIB1 in 1997. It was originally found in blood platelets. CIB1 keeps blood platelets from sticking together, acting as a natural anti-coagulant to prevent clots that might lead to heart attacks or strokes. But further research showed CIB1 appears in almost every cell type in the body, Parise said. For example, male mice bred without both copies of the CIB1 gene are infertile.
In the current study, Parise and her colleagues found CIB1 in the endothelial cells that line all blood vessels. These cells jump-start new blood vessel growth via a process called angiogenesis. During angiogenesis, biological signals prompt endothelial cells to release enzymes and other chemicals that allow them to move away from existing blood vessels and form new ones.
While angiogenesis plays a critical role in embryo growth, CIB1 appears to only affect blood vessel growth after injury (sometimes called pathological or adaptive angiogenesis). Mice born without copies of the CIB1 gene survive and are reasonably healthy unless injured, Parise said.
"CIB1 appears to be an attractive drug target to control blood vessel growth since it does not play an essential role during fetal development but instead plays an important role in pathological forms of blood vessel growth," said first author and medical student at UNC Mohamed Zayed, Ph.D.
In experiments in mice missing CIB1 genes, the researchers found that CIB1 is critical for angiogenesis in the retina, as well as angiogenesis in hind legs. In both cases, the new blood vessel growth was prompted by ischemia, or restricted blood flow. However, clinicians treating retinal disease need to restrict blood vessel growth in the eyes, while patients with restricted blood flow in their limbs need to grow need blood vessels. Therefore, CIB1 could be a target for both pro- and anti-angiogenic drug therapies.
Parise notes that the lab is still determining the exact role CIB1 plays in angiogenesis. "We think it's involved in the chemical pathways that control blood vessel growth, such as signal transduction events," she said. It is also likely that CIB1 is one of many genes that contribute to angiogenesis during ischemia, inflammation and perhaps even tumor growth.
University of North Carolina at Chapel Hill
The results will appear in an upcoming print issue of the journal Circulation Research and were published online Nov. 1, 2007. The research was funded by the National Institutes of Health.
Parise's lab first discovered the protein, called CIB1 in 1997. It was originally found in blood platelets. CIB1 keeps blood platelets from sticking together, acting as a natural anti-coagulant to prevent clots that might lead to heart attacks or strokes. But further research showed CIB1 appears in almost every cell type in the body, Parise said. For example, male mice bred without both copies of the CIB1 gene are infertile.
In the current study, Parise and her colleagues found CIB1 in the endothelial cells that line all blood vessels. These cells jump-start new blood vessel growth via a process called angiogenesis. During angiogenesis, biological signals prompt endothelial cells to release enzymes and other chemicals that allow them to move away from existing blood vessels and form new ones.
While angiogenesis plays a critical role in embryo growth, CIB1 appears to only affect blood vessel growth after injury (sometimes called pathological or adaptive angiogenesis). Mice born without copies of the CIB1 gene survive and are reasonably healthy unless injured, Parise said.
"CIB1 appears to be an attractive drug target to control blood vessel growth since it does not play an essential role during fetal development but instead plays an important role in pathological forms of blood vessel growth," said first author and medical student at UNC Mohamed Zayed, Ph.D.
In experiments in mice missing CIB1 genes, the researchers found that CIB1 is critical for angiogenesis in the retina, as well as angiogenesis in hind legs. In both cases, the new blood vessel growth was prompted by ischemia, or restricted blood flow. However, clinicians treating retinal disease need to restrict blood vessel growth in the eyes, while patients with restricted blood flow in their limbs need to grow need blood vessels. Therefore, CIB1 could be a target for both pro- and anti-angiogenic drug therapies.
Parise notes that the lab is still determining the exact role CIB1 plays in angiogenesis. "We think it's involved in the chemical pathways that control blood vessel growth, such as signal transduction events," she said. It is also likely that CIB1 is one of many genes that contribute to angiogenesis during ischemia, inflammation and perhaps even tumor growth.
University of North Carolina at Chapel Hill
Blood Vessel Current Events and Blood Vessel News RSSResearchers Identify Role of Gene in Tumor Development, Growth and Progression
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.
Effect of real-time CPR feedback reported at resuscitation science symposium
Emergency medical service (EMS) providers in the United States assess an estimated 350,000 cardiac arrests each year. Only 5 to 10 percent of people who have sudden cardiac arrest survive. Better quality cardiopulmonary resuscitation (CPR) provided by prehospital EMS providers may be associated with better patient outcome.
Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests.
Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature
Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
Key player identified in cascade that leads to hypertension-related kidney damage
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both.
Blood vessels might predict prostate cancer behavior
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
Sight gone, but not necessarily lost?
Like all tissues in the body, the eye needs a healthy blood supply to function properly. Poorly developed blood vessels can lead to visual impairment or even blindness.
Stanford study recommends change in treating pulmonary embolisms
William Kuo, MD, was the on-call interventional radiologist one Friday night three years ago when he received a call from the intensive care unit at Stanford Hospital & Clinics.
Clots traveling from lower veins may not be the cause of pulmonary embolism in trauma patients
A report from a team of Massachusetts General Hospital (MGH) physicians calls into question the longstanding belief that pulmonary embolism (PE) - the life-threatening blockage of a major blood vessel in the lungs - is caused in trauma patients by a blood clot traveling from vessels deep within the legs or lower torso.
More Blood Vessel Current Events and Blood Vessel News Articles
 |
The Fluid Mechanics of Large Blood Vessels (Cambridge Monographs on Mechanics) by T. J. Pedley (Author) The analysis of the circulation of the blood is one of the most important areas of fluid mechanics research, with far-reaching medical and physiological implications. |
|
Muscles and Blood Vessels Starring: Medical Student Directed By: Bill Barnett Medicines that aid the treatment of muscles and blood vessels is one of the research interests of an Asian medical student at the Morehouse School of Medicine. He discusses his research and how he manages the challenges of working toward a medical degree | |
 |
EcoNugenics PectaSol-C¿ Modified Citrus Pectin (270 V-caps/800mg), 0.68 lb Plastic Bottle by EcoNugenics PectaSol-C® modified citrus pectin is a highly absorbable soluble dietary fiber. This natural product is derived from the pith of citrus fruits, and is modified utilizing an enhanced process resulting in improved molecular weight and chain characteristics. PectaSol-C® product is recognized primarily for its ability to promote healthy cell growth and proliferation. |
 |
Blood Vessels - Blood Vessels - Cd, 2006 THIS IS BLOOD VESSELS - "BLOOD VESSELS" CD - 2006. SONGS: 1 Catholic Zombies 2 Escape from My Brain 3 Not Funny 4 So Long 5 When You're Young 6 Primal Urge 7 Don't Care 8 Hell Rocket 9 White Knuckle Grip 10 Complacency |
|
Mosby's Physical Examination Video Series: Video 8: Blood Vessels, Version 2 [VHS] Starring: Henry M. Seidel MD, Jane W. Ball RN DrPH CPNP NAP, Joyce E. Dains DrPH JD RN FNP BC NAP, G. William Benedict MD PhD | |
|
Blood Vessel by Blood Vessel | |
 |
Blood Vessels 101 Canvas Print - Canvas Art by FineArtAmerica.com This is a beautiful stretched-canvas art print wrapped on 2.5" thick stretcher bars. The print is professionally printed, assembled, and shipped within 2 - 3 business days from our production facility in North Carolina and arrives ready-to-hang on your wall. FineArtAmerica.com is home to more than 20,000 artists from all over the world who entrust us to fulfill their print orders online. We offer a 30-day money-back guarantee on every print that we sell and look forward to helping you select your next piece. |
 |
Blood Vessel The Cassandra Complex (Primary Contributor) |
 |
Heart Model; 3 Times Life-Size; Opens to Show Valves, Blood Vessels, Musculature by Neo/Sci Corporation Models, anatomical and cellular; Heart; 3x life-size; Separates into 4 parts; Sectioned; Shows ventricles, atria as open to expose valves, showing large blood vessels near heart and musculature of heart; Base-mounted; 7.5 x 9 x 12 in. |
 |
L-Arginine Sustained Release 350mg 360 Tablets by Healthy Origins Robert E. Kowalskys new book details entirely new, natural approaches to lowering blood pressure. His revolutionary program eliminates the need for prescription drugs for most people. He advocates L-Arginine-SR as an important part of that program. Healthy Origins® L-Arginine-SR is a unique formulation that utilizes a sustained release delivery system specifically manufactured to release the L-Arginine continuously over a 5-7 hour period. |
| © 2009 BrightSurf.com |